Lineage Cell Therapeutics (LCTX) Misses Q4 EPS by 12c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.17), $0.12 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $640 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT